問卷

TPIDB > Search Result

Search Result

篩選

List

80Cases

2025-11-01 - 2027-08-22

Phase II

Not yet recruiting
A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
  • Condition/Disease

    Nausea 、Vomiting 、Drug-Related Side Effects and Adverse Reactions 、Neoplasms

  • Test Drug

    subcutaneous injection

Participate Sites
5Sites

Recruiting5Sites

2025-06-18 - 2027-12-31

Phase I

Not yet recruiting
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
  • Condition/Disease

    Neoplasms

  • Test Drug

    Injectable

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    Subcutaneous injection Injection Injection Injection Injection

Participate Sites
7Sites

Recruiting7Sites

2021-04-01 - 2033-02-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-10-01 - 2024-07-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

2019-05-01 - 2025-12-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-09-01 - 2025-03-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2021-12-04 - 2024-09-30

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-03-01 - 2028-06-30

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-11-01 - 2024-05-13

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites